CA2619217A1 - Neurorestoration with r(+) pramipexole - Google Patents

Neurorestoration with r(+) pramipexole Download PDF

Info

Publication number
CA2619217A1
CA2619217A1 CA002619217A CA2619217A CA2619217A1 CA 2619217 A1 CA2619217 A1 CA 2619217A1 CA 002619217 A CA002619217 A CA 002619217A CA 2619217 A CA2619217 A CA 2619217A CA 2619217 A1 CA2619217 A1 CA 2619217A1
Authority
CA
Canada
Prior art keywords
pramipexole
formulation
enantiomer
daily
tetrahydrobenzathiazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002619217A
Other languages
English (en)
French (fr)
Inventor
James P. Bennett, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UVA Licensing and Ventures Group
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2619217A1 publication Critical patent/CA2619217A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002619217A 2005-08-15 2006-08-15 Neurorestoration with r(+) pramipexole Abandoned CA2619217A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70821305P 2005-08-15 2005-08-15
US60/708,213 2005-08-15
PCT/US2006/031831 WO2007022182A1 (en) 2005-08-15 2006-08-15 Neurorestoration with r(+) pramipexole

Publications (1)

Publication Number Publication Date
CA2619217A1 true CA2619217A1 (en) 2007-02-22

Family

ID=37428609

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002619217A Abandoned CA2619217A1 (en) 2005-08-15 2006-08-15 Neurorestoration with r(+) pramipexole

Country Status (10)

Country Link
US (3) US20080234338A1 (enExample)
EP (1) EP1917014B1 (enExample)
JP (2) JP2009504748A (enExample)
AT (1) ATE444750T1 (enExample)
AU (1) AU2006279643B2 (enExample)
CA (1) CA2619217A1 (enExample)
DE (1) DE602006009670D1 (enExample)
ES (1) ES2334061T3 (enExample)
IL (1) IL189512A (enExample)
WO (1) WO2007022182A1 (enExample)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9642840B2 (en) 2013-08-13 2017-05-09 Knopp Biosciences, Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9763918B2 (en) 2013-08-13 2017-09-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
US9849116B2 (en) 2008-08-19 2017-12-26 Knopp Biosciences Llc Compositions and methods of using (R)-pramipexole
US10179774B2 (en) 2007-03-14 2019-01-15 Knopp Biosciences Llc Synthesis of chirally purified substituted benzothiazole diamines
US10383857B2 (en) 2013-07-12 2019-08-20 Knopp Biosciences Llc Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
KR20040066890A (ko) * 2001-12-11 2004-07-27 유니버시티 오브 버지니아 페이턴트 파운데이션 근위축성 측삭 경화증 치료를 위한 프라미펙솔의 용도
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
ME01316B (me) 2004-08-13 2013-12-20 Boehringer Ingelheim Int Formulacija tablete sa produženim oslobađanjem koji sadrži pramipeksol ili njegovu farmaceutski prihvatljivu so
UA88477C2 (ru) 2004-08-13 2009-10-26 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
ATE444750T1 (de) * 2005-08-15 2009-10-15 Univ Virginia Neurorestauration mit r(+) pramipexol
WO2007090882A2 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Pharmaceutical extended release compositions comprising pramipexole
EP2465500A1 (en) * 2006-05-16 2012-06-20 Knopp Neurosciences, Inc. Therapeutically effective amounts of R(+) and S(-) pramipexole for use in the treatment of parkinson's disease
CN102160865A (zh) 2006-05-16 2011-08-24 诺普神经科学股份有限公司 R(+)和s(-)普拉克索的组合物以及使用该组合物的方法
WO2008074033A1 (en) * 2006-12-14 2008-06-19 Knopp Neurosciences, Inc. Compositions and methods of using (r)-pramipexole
CN101677564A (zh) * 2007-03-14 2010-03-24 诺普神经科学股份有限公司 (6r)-4,5,6,7-四氢-n6-丙基-2,6-苯并噻唑-二胺的改良释放制剂及其使用方法
KR20100016270A (ko) * 2007-05-11 2010-02-12 산텐 세이야꾸 가부시키가이샤 비맥각계의 선택적 ｄ2 수용체 작용제를 유효 성분으로서 함유하는 후안부 질환의 예방 또는 치료제
GB0721333D0 (en) * 2007-10-31 2007-12-12 Motac Neuroscience Ltd Medicaments
AU2010234244A1 (en) * 2009-04-09 2011-10-13 Purdue Pharma Once-daily oral IR/CR pramipexole formulation
AU2010262970A1 (en) * 2009-06-19 2012-01-12 Knopp Neurosciences, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
KR101799429B1 (ko) 2010-05-03 2017-11-21 에스케이바이오팜 주식회사 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
WO2016194015A2 (en) * 2015-06-04 2016-12-08 Chiarugi Alberto Use of r(+)-pramipexole (dexpramipexole) for the treatment of cerebral ischemia of the focal type
WO2018183192A1 (en) * 2017-03-27 2018-10-04 Chase Therapeutics Corporation Compositions and methods for treating synucleinopathies
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572485D1 (en) * 1984-12-22 1989-09-28 Thomae Gmbh Dr K Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
DE3937271A1 (de) * 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
US6156777A (en) * 1994-12-15 2000-12-05 Pharmacia & Upjohn Company Use of pramipexole as a neuroprotective agent
US5650420A (en) * 1994-12-15 1997-07-22 Pharmacia & Upjohn Company Pramipexole as a neuroprotective agent
ES2159362T3 (es) * 1995-10-26 2001-10-01 Sanofi Synthelabo Utilizacion de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropiridina para la preparacion de medicamentos destinados para el tratamiento de la esclerosis lateral amiotrofica.
GB9705428D0 (en) * 1997-03-15 1997-04-30 Knoll Ag Therapeutic agents
US6197339B1 (en) * 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
PE20000728A1 (es) * 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
DE19830201A1 (de) * 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Mittel mit antidepressiver Wirkung
CA2301899C (en) * 1998-07-27 2008-11-18 Boehringer Ingelheim Pharma Kg Agent with an antidepressant activity
IL142896A0 (en) * 1998-11-02 2002-04-21 Elan Corp Plc Multiparticulate modified release composition
CA2415815A1 (en) * 2000-07-06 2002-01-17 Nigel H. Greig Tetrahydrobenzothiazole analogues as neuroprotective agents
DE10037619A1 (de) * 2000-08-02 2002-02-14 Daimler Chrysler Ag Anordnung von Bedienelementen
ES2187249B1 (es) * 2000-09-18 2004-09-16 Synthon Bv Procedimiento para la preparacion de 2-amino-6-(alquil)amino-4,5,6,7-tetrahidrobenzotiazoles.
US20020151526A1 (en) * 2000-10-06 2002-10-17 Gallop Mark A. Bile-acid prodrugs of L-dopa and their use in the sustained treatment of parkinsonism
DE10137082A1 (de) * 2001-07-28 2003-02-13 Hexal Ag Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol
KR20040066890A (ko) * 2001-12-11 2004-07-27 유니버시티 오브 버지니아 페이턴트 파운데이션 근위축성 측삭 경화증 치료를 위한 프라미펙솔의 용도
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
US6927036B2 (en) * 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
PT1485078E (pt) * 2002-03-15 2013-01-14 Cypress Bioscience Inc Milnacipran para o tratamento do síndrome do intestino irritável
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
SI1610791T1 (sl) * 2003-03-31 2011-05-31 Titan Pharmaceuticals Inc Implantibilna polimerna naprava za zadržano sproščanje dopaminskega agonista
WO2005010011A2 (en) * 2003-07-15 2005-02-03 Xenoport, Inc. Methods of synthesis of acyloxyalkyl compounds
DE10333393A1 (de) * 2003-07-23 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System mit dem Wirkstoff Pramipexol
UA88477C2 (ru) * 2004-08-13 2009-10-26 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
TW200616604A (en) * 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
ATE444750T1 (de) * 2005-08-15 2009-10-15 Univ Virginia Neurorestauration mit r(+) pramipexol

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
US10179774B2 (en) 2007-03-14 2019-01-15 Knopp Biosciences Llc Synthesis of chirally purified substituted benzothiazole diamines
US9849116B2 (en) 2008-08-19 2017-12-26 Knopp Biosciences Llc Compositions and methods of using (R)-pramipexole
US10208003B2 (en) 2011-12-22 2019-02-19 Knopp Biosciences Llc Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9956206B2 (en) 2013-02-28 2018-05-01 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US10285981B2 (en) 2013-02-28 2019-05-14 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US10828284B2 (en) 2013-07-12 2020-11-10 Knopp Biosciences Llc Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils
US12138249B2 (en) 2013-07-12 2024-11-12 Areteia Therapeutics, Inc. Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils
US11612589B2 (en) 2013-07-12 2023-03-28 Areteia Therapeutics, Inc. Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils
US11026928B2 (en) 2013-07-12 2021-06-08 Knopp Biosciences Llc Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
US10383856B2 (en) 2013-07-12 2019-08-20 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
US10383857B2 (en) 2013-07-12 2019-08-20 Knopp Biosciences Llc Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils
US10980783B2 (en) 2013-07-12 2021-04-20 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
US9642840B2 (en) 2013-08-13 2017-05-09 Knopp Biosciences, Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
US10456381B2 (en) 2013-08-13 2019-10-29 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
US10195183B2 (en) 2013-08-13 2019-02-05 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
US9763918B2 (en) 2013-08-13 2017-09-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
US10028940B2 (en) 2013-08-13 2018-07-24 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders

Also Published As

Publication number Publication date
US20110218222A1 (en) 2011-09-08
EP1917014B1 (en) 2009-10-07
US20130116292A1 (en) 2013-05-09
WO2007022182A1 (en) 2007-02-22
AU2006279643B2 (en) 2010-06-17
ES2334061T3 (es) 2010-03-04
IL189512A (en) 2013-03-24
EP1917014A1 (en) 2008-05-07
AU2006279643A1 (en) 2007-02-22
JP2009504748A (ja) 2009-02-05
IL189512A0 (en) 2011-08-01
US20080234338A1 (en) 2008-09-25
DE602006009670D1 (de) 2009-11-19
JP2013014629A (ja) 2013-01-24
ATE444750T1 (de) 2009-10-15

Similar Documents

Publication Publication Date Title
EP1917014B1 (en) Neurorestoration with r(+) pramipexole
US20060281797A1 (en) Neurorestoration with R(+) Pramipexole
EP1833467B1 (en) Pharmaceutical compositions for sleep disorders
US8017598B2 (en) Compositions of R(+) and S(−) pramipexole and methods of using the same
US20080014271A1 (en) Novel pharmaceutical compositions comprising levetiracetam
CA2460000A1 (en) Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
JP7006990B2 (ja) 眼障害の処置のための組成物及び方法
BRPI0710405A2 (pt) comprimido de racecadotril, processo de preparação de um comprimido de racecadotril e uso de racecadotril
CN103118666A (zh) 含有利福昔明的药物制剂、制备其的方法和治疗肠疾病的方法
HUE030963T2 (en) Sustained release formulations containing a 2-oxo-pyrrolidine derivative
EP2251009B9 (en) Prophylactic or therapeutic agent for ocular disease accompanied by optic nerve disorder
CN101618036A (zh) 羧胺三唑及其可用盐的医药新用途
US20050182097A1 (en) Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
MX2008012729A (es) Inhibidores de renina para el tratamiento de hipertension.
JP2009235069A (ja) ３’，５−ジ−２−プロペニル−（１，１’−ビフェニル）−２，４’−ジオールを有効成分として含有する視神経障害の予防又は治療剤
CN102215842A (zh) 含有吡啶-3-甲醛o-(哌啶-1-基-丙基)-肟衍生物作为有效成分的脉络膜视网膜变性疾病的治疗剂
WO2004105756A2 (en) Combination comprising (a) a neuroprotecting agent and (b) an agent binding to gadph and pharmaceutical use thereof
US20060063842A1 (en) Hypogastric and/or perineal pain-relieving agent
EP3810112A2 (en) A combination comprising fingolimod and modafinil
JP2006348024A (ja) アミジノ誘導体を有効成分として含む神経細胞の保護剤
HK1159502A (en) Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued